Flow cytometry analysis of PBMCs from this trial showed that although placebo had no effect on ILC2 populations, patients receiving 1.5 MIU/d of IL-2 for 5 consecutive days showed a trend toward a decrease in ILC2 canonical markers CRTH2 and CD127 immediately after the treatment course (follow-up 1), which then recovered after 1 week (follow-up 2) ( Figure 7D ).
← all excerpts
Innate Lymphoid Cells Promote Recovery of Ventricular Function After Myocardial Infarction.
1
—
—